Clinical Trial Update: Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ARO-APOC3 in healthy volunteers and patients with hypertriglyceridemia or familial chylomicronemia syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome
• Hypertriglyceridemia

Drugs mentioned

• ARO-APOC3 (APOC3 antisense oligonucleotide)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Hypertriglyceridemia, Familial Chylomicronemia | Phase 1 | Status: COMPLETED